Please use this identifier to cite or link to this item:
|Title:||Pilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery.|
|Authors:||Prowle, John R;Calzavacca, Paolo;Licari, Elisa;Ligabo, Emmanuela V;Echeverri, Jorge E;Haase, Michael;Haase-Fielitz, Anja;Bagshaw, Sean M;Devarajan, Prasad;Bellomo, Rinaldo|
|Affiliation:||Department of Intensive Care, Austin Health, Heidelberg, Victoria, Australia|
|Citation:||Nephrology (carlton, Vic.); 17(3): 215-24|
|Abstract:||To test whether short-term perioperative administration of oral atorvastatin could reduce incidence of postoperative acute kidney injury (AKI) in cardiac surgical patients.We conducted a double-blind, randomized controlled trial in 100 cardiac surgical patients at increased risk of postoperative AKI. Patients were randomized to atorvastatin (40 mg once daily for 4 days starting preoperatively) or identical placebo capsule. Primary outcome was to detect a smaller absolute rise in postoperative creatinine with statin therapy. Secondary outcomes included AKI defined by the creatinine criteria of RIFLE consensus classification (RIFLE R, I or F), change in urinary neutrophil gelatinase-associated lipocalin (NGAL) concentration, requirement for renal replacement therapy, length of stay in intensive care, length of stay in hospital and hospital mortality.Study groups were well matched. For each patient maximal increase in creatinine during the 5 days after surgery was assessed; median maximal increase was 28 µmol/L in the atorvastatin group and 29.5 µmol/L in the placebo group (P = 0.62). RIFLE R or greater occurred in 26% of patients with atorvastatin and 32% with placebo (P = 0.65). Postoperatively urine NGAL changes were similar (median NGAL : creatinine ratio at intensive care unit admission: atorvastatin group 1503 ng/mg, placebo group 1101 ng/mg; P = 0.22). Treatment was well tolerated and adverse events were similar between groups.Short-term perioperative atorvastatin use was not associated with a reduced incidence of postoperative AKI or smaller increases in urinary NGAL. (ClinicalTrials.gov NCT00910221).|
|Internal ID Number:||22117606|
|Subjects:||Acute Kidney Injury.prevention & control|
Cardiac Surgical Procedures.adverse effects
Heptanoic Acids.therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors.therapeutic use
Postoperative Complications.prevention & control
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.